Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.

Autor: Joshi S; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California. ddurden@ucsd.edu shjoshi@ucsd.edu., Singh AR; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California., Liu KX; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California., Pham TV; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California., Zulcic M; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California., Skola D; Division of Biological Sciences, University of California San Diego, San Diego, California., Chun HB; Division of Biological Sciences, University of California San Diego, San Diego, California., Glass CK; Division of Biological Sciences, University of California San Diego, San Diego, California., Morales GA; SignalRx Pharmaceuticals, San Diego, California., Garlich JR; SignalRx Pharmaceuticals, San Diego, California., Durden DL; UCSD Department of Pediatrics, Moores UCSD Cancer Center, University of California San Diego, San Diego, California. ddurden@ucsd.edu shjoshi@ucsd.edu.; SignalRx Pharmaceuticals, San Diego, California.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Jun; Vol. 18 (6), pp. 1036-1044. Date of Electronic Publication: 2019 Apr 24.

Association of high microvessel α v β 3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Autor: Erdreich-Epstein A; Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.; Department of Pathology, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Singh AR; Department of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA., Joshi S; Department of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA., Vega FM; Department of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.; Instituto de Biomedicina de Sevilla, IBiS/HUVR/CSIC/Universidad de Sevilla and Department of Medical Physiology and Biophysics, Universidad de Sevilla, Spain., Guo P; Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Xu J; Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Groshen S; Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA., Ye W; Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA., Millard M; Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Campan M; Department of Surgery University of Southern California, Keck School of Medicine, Los Angeles, California, USA., Morales G; SignalRx Pharmaceuticals, San Diego, California, USA., Garlich JR; SignalRx Pharmaceuticals, San Diego, California, USA., Laird PW; Department of Surgery University of Southern California, Keck School of Medicine, Los Angeles, California, USA.; USC Epigenome Center, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.; Current Address: Van Andel Research Institute, Grand Rapids, Michigan, USA., Seeger RC; Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Shimada H; Department of Pathology, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA., Durden DL; Department of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.; SignalRx Pharmaceuticals, San Diego, California, USA.; Department of Pediatrics, UCSD School of Medicine and Rady Children's Hospital San Diego, California, USA.

Publikováno v: Oncotarget [Oncotarget] 2016 Nov 18; Vol. 8 (32), pp. 52193-52210. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2017).

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.

Autor: Singh AR; Department of Pediatrics, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Joshi S; Department of Pediatrics, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Zulcic M; Department of Pediatrics, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Alcaraz M; Department of Pediatrics, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Garlich JR; SignalRx Pharmaceuticals, San Diego, CA, United States of America., Morales GA; SignalRx Pharmaceuticals, San Diego, CA, United States of America., Cho YJ; Departments of Neurology and Neurosurgery, Stanford University School of Medicine, Stanford, CA, United States of America., Bao L; Biostatistics Department, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Levy ML; Department of Neurosurgery, UCSD Rady Children's Hospital, La Jolla, CA, United States of America., Newbury R; Department of Pathology, UCSD Rady Children's Hospital, La Jolla, CA, United States of America., Malicki D; Department of Pathology, UCSD Rady Children's Hospital, La Jolla, CA, United States of America., Messer K; Biostatistics Department, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America., Crawford J; Department of Neurosciences Division of Child Neurology, UCSD Rady Children's Hospital, La Jolla, CA, United States of America., Durden DL; Department of Pediatrics, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, United States of America.; Division of Pediatric Hematology-Oncology, UCSD Rady Children's Hospital, La Jolla, CA, United States of America.

Publikováno v: PloS one [PLoS One] 2016 Mar 03; Vol. 11 (3), pp. e0150836. Date of Electronic Publication: 2016 Mar 03 (Print Publication: 2016).